Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:34:09.000Z.
Calculation as of: 2026-10-06T17:34:09.000Z.
Quote observation: 2026-10-06T16:53:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ef632b76806419539d367682e283305f5302e219c84c42b2c880863f64fefb48
PE RATIO
N/A
Shuttle Pharmaceuticals Holdings, Inc.
Market Cap
$2.37M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.32M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.07M
PE Ratio
N/A
TTM Avg
98120994617.14
3Y Avg
98120994617.14
5Y Avg
98120994617.14
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | $2.37M | N/A | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.37M | N/A | N/A | N/A | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.40M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A | N/A | N/A | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.48M | N/A | N/A | N/A | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.52M | N/A | N/A | N/A | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.55M | N/A | N/A | N/A | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.62M | N/A | 0.58 | 0.58 | 0.58 |
| GeoVax Labs, Inc. (GOVX)vs › | $2.07M | N/A | 98120994617.14 | 98120994617.14 | 98120994617.14 |
| iSpecimen Inc. (ISPC)vs › | $2.72M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
